IQVIA Holdings Inc.

IQV Healthcare Diagnostics & Research

IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS was flat, free cash flow grew 23.3% and total debt rose 3.29%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

266.90 4.14 −1.53%
Market cap
$44.6B
P/E
32.8×
Fwd P/E
22.3×
Dividend yield
—
F-score
4/9
Altman Z
2.05
Beneish M
−2.59
Dividend safety
n/a

IQVIA Holdings Inc. 10-K filed Feb 17, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 7:46 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 13, 2025: 9 added · 16 removed · 22 modified; 14 with only figures updated

  1. Modified · Our Company

    IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected IntelligenceTM to deliver actionable insights and services built on high-quality health data, Healthcare-grade AITMAI®, advanced analytics, the latest technologies and extensive domain expertise. We are committed to using artificial intelligence ("AI") responsibly, ensuring that our with AI-powered capabilities are grounded in built on best-in-class approaches to privacy, regulatory compliance, and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,00093,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, we are dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

46 more changes in this Item, word by word, in Powerpack.

Powerpack